Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Cash: 2022-2025

Historic Change in Cash for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $22.3 million.

  • Axsome Therapeutics' Change in Cash rose 90.48% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 97.68%. This contributed to the annual value of -$70.8 million for FY2024, which is 138.22% down from last year.
  • Per Axsome Therapeutics' latest filing, its Change in Cash stood at $22.3 million for Q3 2025, which was up 956.79% from $2.1 million recorded in Q2 2025.
  • Axsome Therapeutics' Change in Cash's 5-year high stood at $190.6 million during Q2 2023, with a 5-year trough of -$54.8 million in Q1 2024.
  • Moreover, its 3-year median value for Change in Cash was -$12.0 million (2024), whereas its average is $11.3 million.
  • Per our database at Business Quant, Axsome Therapeutics' Change in Cash surged by 2,687.71% in 2023 and then crashed by 219.88% in 2024.
  • Axsome Therapeutics' Change in Cash (Quarterly) stood at -$26.7 million in 2022, then dropped by 13.84% to -$30.4 million in 2023, then skyrocketed by 60.53% to -$12.0 million in 2024, then spiked by 90.48% to $22.3 million in 2025.
  • Its Change in Cash was $22.3 million in Q3 2025, compared to $2.1 million in Q2 2025 and -$14.4 million in Q1 2025.